Opaleye Management Inc. Buys $33K of Grace Therapeutics Inc (GRCE) — SEC Form 4, Nov 06, 2026

Open-Market Net Purchase · SEC Form 4
+$33,019

Equity position changed by +0.6%

Reporting Owner
TXN 2026-11-05 · FILED 2026-11-06
Equity Position 3.05M sh 3,036,411 → 3,054,853
Equity Change +0.6% shares held after vs before
Filing Lag 1 business day within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Filing Date
2026-11-06
Report Date
2026-11-06
Accession No.
0001493152-26-050313
Accepted At
2026-11-06 02:05 UTC
Reporting Owner
Name Relationship
Opaleye Management Inc. CIK 0001595855
10% Owner
Opaleye Management Inc. at Grace Therapeutics Inc Full insider history
Bought (12 mo) $676,929
Sold (12 mo) —
More from this insider at Grace Therapeutics Inc
2026-11-19 Buy +$83,435 View
2026-10-26 Buy +$158,601 View
2026-10-21 Buy +$8,001 View
2026-10-17 Buy +$136,178 View
2026-10-13 Buy +$29,683 View
All filings by this insider at Grace Therapeutics Inc
Non-Derivative Securities Transactions
Title Date Type Shares Price Net Total Post-Txn Ownership
Common Stock, par value $0.0001 per shareF2F1F5 2026-11-03 P - Purchase 10,328 A $1.79 +$18,481 3,046,739 Indirect By Opaleye, L.P.
Common Stock, par value $0.0001 per shareF3F1F5 2026-11-04 P - Purchase 5,027 A $1.80 +$9,060 3,051,766 Indirect By Opaleye, L.P.
Common Stock, par value $0.0001 per shareF4F1F5 2026-11-05 P - Purchase 3,087 A $1.77 +$5,478 3,054,853 Indirect By Opaleye, L.P.
Footnotes (5)
F1
Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Show more
F2
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.775 to $1.79. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range. Show more
F3
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.80 to $1.81. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range. Show more
F4
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.77 to $1.78. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range. Show more
F5
Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. Show more
5%+ Holders · 13D/G 3 filers
Other insiders at Grace Therapeutics Inc
All Grace Therapeutics Inc insider activity
GET /v1/forms/4/0001493152-26-050313 API docs
View Original SEC Filing